Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical‑stage biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life‑threatening diseases. The company is primarily focused on developing programmed hematopoietic cellular candidates as therapeutic entities for the treatment of hematologic malignancies, rare genetic disorders, and diseases resulting from the dysregulation of the immune system. Fate has built a novel platform to program the function and fate of cells ex vivo using pharmacologic modulators, such as small molecules. For more information, visit the company’s website at www.fatetherapeutics.com.